Spinal Muscular Atrophy Type 3
18
4
7
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
2 terminated out of 18 trials
77.8%
-8.7% vs benchmark
11%
2 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (18)
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
Gait and Bone Health in SMA
Spinal Cord Stimulation in Spinal Muscular Atrophy
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
Spinraza in Adult Spinal Muscular Atrophy
Wearable Technology to Assess Gait Function in SMA and DMD
Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy
Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders
Oxidative Capacity and Exercise Tolerance in Ambulatory SMA
Whole Body Vibration Therapy in Children With Spinal Muscular Atrophy